Trans San Francisco reports Trans San Francisco

FDA approves long-acting injectable PrEP

Reading now: 823

The federal Food and Drug Administration has approved Apretude (extended-release cabotegravir), the first long-acting injectable option for HIV prevention.

The shots, which are administered by a health care provider every two months, were more effective than daily PrEP pills in two large studies of gay men, trans women, and cisgender women. "The FDA approval of long-acting injectable cabotegravir is a major breakthrough for the prevention field," Dr.

Susan Buchbinder, director of Bridge HIV at the San Francisco Department of Public Health, said in a statement from the International AIDS Society. "Some people aren't able to, or don't want to, take PrEP pills.

The website is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News